Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Fig. FACS analysis of SIRPα/β on HEK293/Human SIRP alpha Stable Cell Line.
FACS assay shows that Anti-SIRPα/β antibody can bind to HEK293/Human SIRP alpha Stable Cell Line. HEK293/Human SIRP alpha Stable Cell Line was red line, Negative control HEK293 cells was grey line (QC tested).
5e5 of overexpressing mouse CD47 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Mouse SIRP alpha, His Tag (Cat. No. SIA-MP2H6) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
Loaded Human CD47, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. CD7-H52A5) on Protein A Biosensor, can bind Human SIRP alpha, His Tag (Cat. No. SIA-H5225) with an affinity constant of 1.1 μM as determined in BLI assay (ForteBio Octet Red96e) (QC tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Relugolix/Estradiol/Norethindrone Acetate | E2/NETA | Approved | Myovant Sciences | MYFEMBREE, RYEQO | United States | Menorrhagia; Leiomyoma | Myovant Sciences | 2021-05-26 | Pain; Endometriosis; Leiomyoma; Menorrhagia; Uterine Neoplasms | Details |
| Elagolix/estradiol/norethindrone acetate | Approved | Abbvie Inc | Oriahnn | United States | Menorrhagia | Abbvie Inc | 2020-05-29 | Menorrhagia | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| LM-101 | LM-101 | Phase 2 Clinical | LaNova Medicines Ltd | Solid tumours; Hematologic Neoplasms; Leukemia; Neoplasms | Details |
| BI-770371 | BI-770371 | Phase 2 Clinical | C.H. Boehringer Sohn Ag & Co. Kg, Ose Immunotherapeutics | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Metabolic Dysfunction-Associated Steatotic Liver Disease; Liver Cirrhosis; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| IBC-0966 | IBC-0966 | Phase 2 Clinical | SunHo (China) BioPharmaceutical Co Ltd | Neoplasms | Details |
| BI-765063 | OSE-172; BI-765063; Effi-DEM | Phase 1 Clinical | Effimune | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular | Details |
| Anzurstobart | BMS-986351; CC-95251 | Phase 1 Clinical | Celgene Corp | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| ADU-1805 | ADU-1805 | Phase 1 Clinical | Aduro Biotech Inc | Solid tumours; Neoplasms | Details |
| Q-1801 | Q-1801; Q 1801 | Phase 1 Clinical | Qiyu Biotechnology (Shanghai) Co Ltd | Solid tumours | Details |
| BRB-002 | BRB-002 | Phase 1 Clinical | Bitterroot Bio Inc | Atherosclerosis; Vasculitis; Cardiovascular Diseases | Details |
| Recombinant humanized IgG4 anti-SIRPα antibody（Daiichi Sankyo） | DS-1103a | Phase 1 Clinical | Daiichi Sankyo Co Ltd | Solid tumours; Breast Neoplasms | Details |
| ELA-026 | ELA-026 | Phase 1 Clinical | Electra Therapeutics Inc | Lymphohistiocytosis, Hemophagocytic | Details |
| BYON-4228 | BYON-4228 | Phase 1 Clinical | Byondis Bv | Solid tumours; Lymphoma | Details |
| BSI-082 | BSI-082 | Phase 1 Clinical | Boaoxin Biotechnology(Nanjing) Co Ltd | Hematologic Neoplasms; Solid tumours | Details |
| BR-105 | BR-105; BR105 | Phase 1 Clinical | Hisun Biopharmaceutical Co Ltd, BioRay Pharmaceutical Co Ltd | Neoplasms; Lymphoma, Large B-Cell, Diffuse | Details |
| [89Zr]Zr- BI-765063(Boehringer Ingelheim) | Phase 1 Clinical | Boehringer Ingelheim Corp | Squamous Cell Carcinoma of Head and Neck; Melanoma; Carcinoma, Non-Small-Cell Lung | Details | |
| TQB-2928 | TQB-2928 | Phase 1 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Hematologic Neoplasms; Solid tumours; Myelodysplastic Syndromes; Neoplasms; Osteosarcoma; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung | Details |
| BI-765080 | Phase 1 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Details | ||
| ES-004 | ES-004; ES 004-N4; ES 004-B4 | Phase 1 Clinical | Elpiscience (Shanghai) Biopharma Ltd | Solid tumours; Neoplasms | Details |
This web search service is supported by Google Inc.
A-Z
